Medicare Update: Court Rules on Seniors' Drug Price Negotiations
Summary
A federal appeals court upheld key parts of the Inflation Reduction Act that let Medicare negotiate drug prices for seniors. The court rejected a lawsuit by drug companies that claimed the program was unconstitutional.Key Facts
- The U.S. Court of Appeals for the Fifth Circuit ruled in favor of the government on Medicare drug price negotiations.
- Pharmaceutical groups like PhRMA challenged the program, saying it violates constitutional rights.
- The court said drug companies do not have a guaranteed right to set prices when participating in Medicare.
- Participation in Medicare and Medicaid by drug companies is voluntary.
- The ruling supports the Inflation Reduction Act signed into law in 2022.
- Similar lawsuits by big drugmakers like Merck and AstraZeneca were also rejected.
- The U.S. Supreme Court refused to hear several challenges to the program earlier this year.
- The program aims to lower prescription drug costs for seniors and taxpayers by allowing price negotiations.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
